-
27 Juillet 2023
-
27 Juillet 2023
Ipsen delivers solid H1 2023 results and upgrades its full-year guidance
The performance in the first half of the year is reflected in today’s upgrade to our full-year guidance. We look forward to more milestones and further expansion of the pipeline over time through additional external-innovation transactions. I am confiden...
-
31 Juillet 2025
-
31 Juillet 2025
Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance
“Our half year results reflect continued strong momentum, with growth across all three therapeutic areas, particularly in our rare liver disease franchise, which is expanding rapidly and progressing well,” said David Loew, Chief Executive Officer, Ipse...
-
27 Avril 2023
-
27 Avril 2023
Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance
Paris (France), 27 April 2023...
-
23 Décembre 2022
-
23 Décembre 2022
Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva
PARIS, FRANCE, 23 December 2022 – The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application for palovarotene, an investigational treatment for the reduction of new abnormal bone formation ...
-
14 Décembre 2022
-
14 Décembre 2022
Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva
PARIS, FRANCE, 23 December 2022 – The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application for palovarotene, an investigational treatment for the reduction of new abnormal bone formation ...
-
05 Septembre 2022
-
05 Septembre 2022
First international Fibrodysplasia Ossificans Progressiva (FOP) Burden of Illness Survey reveals extent of social, economic, and quality of life impact of disease
Findings published in the Expert Review of Pharmacoeconomics & Outcomes Research demonstrate progressive loss of joint mobility and function is associated with a considerable, negative impact on quality of life for those living with FOPSurvey co-create...
-
05 Septembre 2022
- 5 mn de lecture
-
05 Septembre 2022
- 5 mn de lecture
‘A Life in a Day’: the realities of living with FOP
I was honored to be invited to take on the challenge to live ‘A Life in a Day of a patient with FOP’ – but also apprehensive. The challenge simulated a day spent living as someone who has fibrodysplasia ossificans progressiva (FOP). FOP is a debilita...
-
28 Septembre 2022
-
28 Septembre 2022
Ipsen’s global Natural History Study of Fibrodysplasia Ossificans Progressiva shows debilitating impact of the disease over an individual’s lifetime
First prospective study to assess the association of fibrodysplasia ossificans progressive (FOP) flare-ups and extra-skeletal bone growth (heterotopic ossification or HO) with functional impairment...
-
29 Juin 2022
- 6 mn de lecture
-
29 Juin 2022
- 6 mn de lecture
Ipsen announces U.S. FDA Priority Review for palovarotene New Drug Application in patients with fibrodysplasia ossificans progressiva following resubmission
PARIS, France, 29 June 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its resubmitted New Drug Application (NDA) for investigational palovarotene for the tre...
-
28 Septembre 2022
-
28 Septembre 2022
L’étude mondiale d’Ipsen, intitulée « Natural History Study of Fibrodysplasia Ossificans Progressiva », démontre l’impact invalidant de la maladie sur la vie des patients
Première étude prospective réalisée pour évaluer l’association des poussées de fibrodysplasie ossifiante progressive (FOP) et de la croissance osseuse extra-squelettique (ossification hétérotopique ou OH) avec une déficience fonctionnelle...